On May 1, 2026, the updated ASTM F2100-26 standard for medical masks enters into force, introducing new performance requirements for inner-layer skin-contact materials—specifically mandating ‘moisture retention and barrier repair’ functionality. This development directly elevates demand for high-purity sodium hyaluronate (≥95% NaHA) and anti-wrinkle peptides (e.g., acetyl hexapeptide-8) in U.S.-bound medical cold compresses, post-procedural recovery films, and other Class II medical devices manufactured or supplied from China. Exporters must now provide USP <1053> viscosity testing reports and ISO 10993-5 cytotoxicity test data alongside product submissions.

Event Overview

The ASTM F2100-26 standard officially takes effect on May 1, 2026. It newly specifies that the inner layer of medical masks must demonstrate measurable ‘moisture retention and barrier repair’ performance. To meet this, the standard explicitly encourages inclusion of ≥0.1% high-purity sodium hyaluronate (≥95% NaHA) and anti-wrinkle peptides such as acetyl hexapeptide-8. While the standard applies to masks, its material-performance criteria are being referenced by FDA reviewers and notified bodies for adjacent wound care and recovery device categories—including medical cold compresses and post-surgical recovery membranes classified as Class II medical devices. Suppliers exporting such products from China are now required to submit USP <1053> viscosity test results and ISO 10993-5 cytotoxicity reports as part of regulatory documentation.

Industries Affected by This Update

Direct Exporters of Chinese-Made Medical Cold Compresses and Recovery Films

These enterprises face revised documentation expectations for U.S. market access. The ASTM F2100-26 language—though written for masks—is increasingly cited in FDA pre-submission feedback for analogous dermal-contact devices. As a result, exporters may encounter additional requests for functional claims substantiation, particularly around hydration and epidermal barrier support.

Chinese HA and Peptide Raw Material Suppliers

Suppliers of sodium hyaluronate and cosmetic-grade peptides must now align with medical-device-grade verification protocols. The requirement for ≥95% NaHA purity and supporting USP <1053> viscosity data implies stricter batch-level analytical validation—not just certificate-of-analysis summaries. Similarly, peptide suppliers must ensure their acetyl hexapeptide-8 batches carry ISO 10993-5-compliant cytotoxicity test reports, not generic safety assessments.

Contract Manufacturers and OEMs Producing Medical-Grade Topical Devices

OEM facilities producing cold compresses or recovery films for U.S. brands are now expected to validate formulation–performance linkages. For example, simply listing HA or peptide in the ingredients is insufficient; manufacturers may need to demonstrate how the specified concentration contributes to moisture retention or barrier repair—potentially requiring in vitro barrier function assays or controlled hydration-release testing.

Regulatory Affairs and Quality Assurance Teams Supporting Exports

These teams must reassess technical file structures for Class II devices targeting the U.S. market. ASTM F2100-26 is not legally binding for non-mask devices—but its adoption as a benchmark in FDA guidance documents means it functions de facto as an expectation. QA documentation now needs traceability between raw material specifications (e.g., HA viscosity grade), finished product performance claims, and standardized biocompatibility evidence.

Key Considerations and Recommended Actions for Stakeholders

Monitor official FDA communications and guidance updates

While ASTM F2100-26 does not formally regulate cold compresses, the FDA has referenced similar ASTM material-performance frameworks in recent 510(k) review letters. Stakeholders should track FDA’s Guidance for Industry: Cold Compresses and Similar Devices for potential revisions referencing F2100-26 principles—and subscribe to FDA’s Device Advice email alerts for emerging expectations.

Prioritize verification readiness for HA and peptide inputs

Exporters should verify whether current HA and peptide suppliers can deliver full USP <1053> viscosity test reports (including method, instrument calibration, temperature control, and shear rate parameters) and ISO 10993-5 cytotoxicity test reports issued by ISO/IEC 17025-accredited labs. If not, initiate supplier qualification reviews now—lead times for retesting or requalification may exceed 8–12 weeks.

Distinguish between policy signal and enforceable requirement

ASTM F2100-26 remains a voluntary consensus standard—not a regulation. Its influence stems from FDA’s use of ASTM standards as recognized methods under 21 CFR §1099. Therefore, compliance is currently a risk-mitigation measure rather than a legal prerequisite. However, absence of supporting data may delay 510(k) clearance or trigger additional information requests during review.

Update internal technical documentation proactively

Manufacturers should revise product specifications, design history files (DHF), and labeling claims to explicitly connect ingredient concentrations (e.g., 0.15% NaHA) to functional outcomes (e.g., ≥4-hour surface hydration retention per ASTM E1965-22). Where applicable, include summary test data—even if not yet mandated—to strengthen submission credibility ahead of anticipated FDA alignment.

Editorial Perspective / Industry Observation

Observably, ASTM F2100-26’s impact extends beyond masks—not as a direct regulatory expansion, but as a functional benchmark gaining traction in FDA reviewer practice. Analysis shows this reflects a broader shift toward performance-based evaluation of dermal-contact materials in Class II devices, especially where claims intersect with skin physiology (e.g., hydration, barrier repair, soothing). From an industry perspective, this update is best understood not as an immediate compliance deadline, but as an early indicator of evolving evidentiary expectations for bioactive ingredient use in medical topical devices. It signals growing emphasis on mechanistic plausibility—not just compositional disclosure—in U.S. regulatory review.

Current monitoring suggests this standard is functioning more as a reference framework than an enforcement tool—at least for non-mask devices—but its adoption in real-world submissions is accelerating. Continued observation is warranted, particularly regarding whether FDA issues formal guidance linking F2100-26 to wound care or recovery device review pathways.

Conclusion

This update underscores a quiet but consequential evolution in U.S. regulatory expectations: material functionality is becoming a documented component of device safety and effectiveness—especially for products contacting compromised or recovering skin. For Chinese exporters and ingredient suppliers, the significance lies less in immediate mandate and more in anticipatory alignment. It is more accurate to interpret ASTM F2100-26’s effect as a directional signal—one that rewards preparedness in analytical verification, claim substantiation, and cross-functional documentation coherence.

Information Sources

• ASTM International: ASTM F2100-26 Standard Specification for Performance of Materials Used in Medical Face Masks (published March 2026, effective May 1, 2026)
• FDA Center for Devices and Radiological Health (CDRH): Guidance documents and publicly available 510(k) summary letters citing ASTM standards (as of Q1 2026)
• USP Chapter <1053> “Viscosity” and ISO 10993-5:2023 “Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity”

Note: Ongoing tracking of FDA’s forthcoming revision to the Cold Compresses Guidance remains recommended; no finalized update has been published as of April 2026.